The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer

BACKGROUND: HER2 is amplified or overexpressed in around 20% of breast cancers (BC). HER2-targeted therapies have significantly improved the prognosis of patients with HER2+ BC, however, de novo and acquired resistance to anti-HER2 treatment is common. Activating mutations in the PIK3CA gene are rep...

Descripción completa

Detalles Bibliográficos
Autores principales: Cataldo, Maria Letizia, De Placido, Pietro, Esposito, Daniela, Formisano, Luigi, Arpino, Grazia, Giuliano, Mario, Bianco, Roberto, De Angelis, Carmine, Veneziani, Bianca Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353540/
https://www.ncbi.nlm.nih.gov/pubmed/37469415
http://dx.doi.org/10.3389/fonc.2023.1108242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353540/
https://www.ncbi.nlm.nih.gov/pubmed/37469415
http://dx.doi.org/10.3389/fonc.2023.1108242

Ejemplares similares